{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:49:53Z","timestamp":1791582593502,"version":"4.3.4"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"DOI":"10.1038\/s43018-026-01125-2","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T10:02:56Z","timestamp":1771581776000},"page":"631-649","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Erythrocyte\u2013anti-PD1 conjugates in persons with advanced solid tumors resistant to anti-PD1\/PDL1: preclinical characterization and results of a phase 1 trial"],"prefix":"10.1038","volume":"7","author":[{"given":"Xiaoqian","family":"Nie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuehua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyun","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurban","family":"Mattursun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9086-4448","authenticated-orcid":false,"given":"Yuxiong","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0143-3353","authenticated-orcid":false,"given":"Tingbo","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7587-312X","authenticated-orcid":false,"given":"Liu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2799-7421","authenticated-orcid":false,"given":"Xiaofei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"key":"1125_CR1","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1126\/science.342.6165.1432","volume":"342","author":"J Couzin-Frankel","year":"2013","unstructured":"Couzin-Frankel, J. Breakthrough of the year 2013. Cancer immunotherapy. Science 342, 1432\u20131433 (2013).","journal-title":"Science"},{"key":"1125_CR2","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707\u2013723 (2017).","journal-title":"Cell"},{"key":"1125_CR3","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.immuni.2018.03.004","volume":"48","author":"MD Wellenstein","year":"2018","unstructured":"Wellenstein, M. D. & de Visser, K. E. Cancer-cell-intrinsic mechanisms shaping the tumor immune landscape. Immunity 48, 399\u2013416 (2018).","journal-title":"Immunity"},{"key":"1125_CR4","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41573-022-00493-5","volume":"21","author":"TK Kim","year":"2022","unstructured":"Kim, T. K., Vandsemb, E. N., Herbst, R. S. & Chen, L. Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. Nat. Rev. Drug Discov. 21, 529\u2013540 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1125_CR5","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41568-021-00347-z","volume":"21","author":"KJ Hiam-Galvez","year":"2021","unstructured":"Hiam-Galvez, K. J., Allen, B. M. & Spitzer, M. H. Systemic immunity in cancer. Nat. Rev. Cancer 21, 345\u2013359 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"1125_CR6","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1172\/JCI80011","volume":"125","author":"L Chen","year":"2015","unstructured":"Chen, L. & Han, X. Anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future. J. Clin. Invest. 125, 3384\u20133391 (2015).","journal-title":"J. Clin. Invest."},{"key":"1125_CR7","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41586-020-2056-8","volume":"579","author":"TD Wu","year":"2020","unstructured":"Wu, T. D. et al. Peripheral T cell expansion predicts tumour infiltration and clinical response. Nature 579, 274\u2013278 (2020).","journal-title":"Nature"},{"key":"1125_CR8","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow, M. A., Sidlow, R. & Hellmann, M. D. Immune-related adverse events associated with immune checkpoint blockade. N. Engl. J. Med. 378, 158\u2013168 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1125_CR9","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aau6085","volume":"4","author":"SM Lewis","year":"2019","unstructured":"Lewis, S. M., Williams, A. & Eisenbarth, S. C. Structure and function of the immune system in the spleen. Sci. Immunol. 4, eaau6085 (2019).","journal-title":"Sci. Immunol."},{"key":"1125_CR10","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.immuni.2013.10.010","volume":"39","author":"V Bronte","year":"2013","unstructured":"Bronte, V. & Pittet, M. J. The spleen in local and systemic regulation of immunity. Immunity 39, 806\u2013818 (2013).","journal-title":"Immunity"},{"key":"1125_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1158\/0008-5472.CAN-20-2339","volume":"81","author":"J Steenbrugge","year":"2021","unstructured":"Steenbrugge, J., De Jaeghere, E. A., Meyer, E., Denys, H. & De Wever, O. Splenic hematopoietic and stromal cells in cancer progression. Cancer Res. 81, 27\u201334 (2021).","journal-title":"Cancer Res."},{"key":"1125_CR12","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1073\/pnas.1113744109","volume":"109","author":"V Cortez-Retamozo","year":"2012","unstructured":"Cortez-Retamozo, V. et al. Origins of tumor-associated macrophages and neutrophils. Proc. Natl Acad. Sci. USA 109, 2491\u20132496 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1125_CR13","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1002\/eji.202048666","volume":"50","author":"E Tavukcuoglu","year":"2020","unstructured":"Tavukcuoglu, E. et al. Human splenic polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC) are strategically located immune regulatory cells in cancer. Eur. J. Immunol. 50, 2067\u20132074 (2020).","journal-title":"Eur. J. Immunol."},{"key":"1125_CR14","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.celrep.2012.08.006","volume":"2","author":"S Ugel","year":"2012","unstructured":"Ugel, S. et al. Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. Cell Rep. 2, 628\u2013639 (2012).","journal-title":"Cell Rep."},{"key":"1125_CR15","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1093\/intimm\/dxh194","volume":"17","author":"Y Iwai","year":"2005","unstructured":"Iwai, Y., Terawaki, S. & Honjo, T. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int. Immunol. 17, 133\u2013144 (2005).","journal-title":"Int. Immunol."},{"key":"1125_CR16","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aam7729","volume":"10","author":"A Prestipino","year":"2018","unstructured":"Prestipino, A. et al. Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. Sci. Transl. Med. 10, eaam7729 (2018).","journal-title":"Sci. Transl. Med."},{"key":"1125_CR17","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.4049\/jimmunol.1004175","volume":"187","author":"DR Getts","year":"2011","unstructured":"Getts, D. R. et al. Tolerance induced by apoptotic antigen-coupled leukocytes is induced by PD-L1+ and IL-10-producing splenic macrophages and maintained by T regulatory cells. J. Immunol. 187, 2405\u20132417 (2011).","journal-title":"J. Immunol."},{"key":"1125_CR18","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1038\/s41591-020-0892-6","volume":"26","author":"BM Allen","year":"2020","unstructured":"Allen, B. M. et al. Systemic dysfunction and plasticity of the immune macroenvironment in cancer models. Nat. Med. 26, 1125\u20131134 (2020).","journal-title":"Nat. Med."},{"key":"1125_CR19","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.122700","volume":"3","author":"F Ordikhani","year":"2018","unstructured":"Ordikhani, F. et al. Targeting antigen-presenting cells by anti-PD-1 nanoparticles augments antitumor immunity. JCI Insight 3, e122700 (2018).","journal-title":"JCI Insight"},{"key":"1125_CR20","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1038\/s41563-020-0755-z","volume":"19","author":"B Ouyang","year":"2020","unstructured":"Ouyang, B. et al. The dose threshold for nanoparticle tumour delivery. Nat. Mater. 19, 1362\u20131371 (2020).","journal-title":"Nat. Mater."},{"key":"1125_CR21","doi-asserted-by":"publisher","first-page":"596104","DOI":"10.3389\/fcimb.2021.596104","volume":"11","author":"M Gualdr\u00f3n-L\u00f3pez","year":"2021","unstructured":"Gualdr\u00f3n-L\u00f3pez, M. et al. Multiparameter flow cytometry analysis of the human spleen applied to studies of plasma-derived EVs from Plasmodium vivax patients. Front. Cell. Infect. Microbiol. 11, 596104 (2021).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"1125_CR22","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.4049\/jimmunol.1800565","volume":"201","author":"HL Anderson","year":"2018","unstructured":"Anderson, H. L., Brodsky, I. E. & Mangalmurti, N. S. The evolving erythrocyte: red blood cells as modulators of innate immunity. J. Immunol. 201, 1343\u20131351 (2018).","journal-title":"J. Immunol."},{"key":"1125_CR23","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/s41422-023-00868-2","volume":"33","author":"Y Huang","year":"2023","unstructured":"Huang, Y. et al. Development of a highly-efficient erythrocyte-drug covalent conjugation platform and its use in treating thrombotic disorders. Cell Res. 33, 887\u2013890 (2023).","journal-title":"Cell Res."},{"key":"1125_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41421-024-00713-9","volume":"10","author":"Y Liu","year":"2024","unstructured":"Liu, Y. et al. Developing an erythrocyte\u2012MHC-I conjugate for cancer treatment. Cell Discov. 10, 99 (2024).","journal-title":"Cell Discov."},{"key":"1125_CR25","doi-asserted-by":"publisher","first-page":"46","DOI":"10.4161\/mabs.26632","volume":"6","author":"CR Behrens","year":"2014","unstructured":"Behrens, C. R. & Liu, B. Methods for site-specific drug conjugation to antibodies. mAbs 6, 46\u201353 (2014).","journal-title":"mAbs"},{"key":"1125_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24767-5","volume":"12","author":"C Geuijen","year":"2021","unstructured":"Geuijen, C. et al. A human CD137\u00d7PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade. Nat. Commun. 12, 4445 (2021).","journal-title":"Nat. Commun."},{"key":"1125_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000400","volume":"8","author":"T Kurino","year":"2020","unstructured":"Kurino, T. et al. Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1\/PD-L1 blockade-sensitive mouse models. J. Immunother. Cancer 8, e000400 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"1125_CR28","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal3604","volume":"9","author":"SP Arlauckas","year":"2017","unstructured":"Arlauckas, S. P. et al. In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. Sci. Transl. Med. 9, eaal3604 (2017).","journal-title":"Sci. Transl. Med."},{"key":"1125_CR29","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jim.2010.12.016","volume":"366","author":"ME Ackerman","year":"2011","unstructured":"Ackerman, M. E. et al. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J. Immunol. Methods 366, 8\u201319 (2011).","journal-title":"J. Immunol. Methods"},{"key":"1125_CR30","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1084\/jem.173.6.1483","volume":"173","author":"SM Canfield","year":"1991","unstructured":"Canfield, S. M. & Morrison, S. L. The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region. J. Exp. Med. 173, 1483\u20131491 (1991).","journal-title":"J. Exp. Med."},{"key":"1125_CR31","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1080\/19420862.2017.1323159","volume":"9","author":"G Dekkers","year":"2017","unstructured":"Dekkers, G. et al. Affinity of human IgG subclasses to mouse Fc gamma receptors. mAbs 9, 767\u2013773 (2017).","journal-title":"mAbs"},{"key":"1125_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.736955","volume":"11","author":"B Lou","year":"2021","unstructured":"Lou, B. et al. Preclinical characterization of GLS-010 (zimberelimab), a novel fully human anti-PD-1 therapeutic monoclonal antibody for cancer. Front. Oncol. 11, 736955 (2021).","journal-title":"Front. Oncol."},{"key":"1125_CR33","doi-asserted-by":"publisher","first-page":"B81","DOI":"10.1158\/2326-6074.TUMIMM18-B81","volume":"8","author":"M Stackhouse","year":"2020","unstructured":"Stackhouse, M. et al. Abstract B81: efficacy of nivolumab, pembrolizumab, and atezolizumab against MC38 colon cancer expressing human PD-1 in transgenic C57BL\/6 mice expressing human PD-1 and PD-L1 checkpoint genes. Cancer Immunol. Res. 8, B81\u2013B81 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"1125_CR34","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1159\/000342229","volume":"39","author":"M Straat","year":"2012","unstructured":"Straat, M., van Bruggen, R., de Korte, D. & Juffermans, N. P. Red blood cell clearance in inflammation. Transfus. Med. Hemother. 39, 353\u2013361 (2012).","journal-title":"Transfus. Med. Hemother."},{"key":"1125_CR35","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1182\/blood-2017-03-745349","volume":"130","author":"JR Byrnes","year":"2017","unstructured":"Byrnes, J. R. & Wolberg, A. S. Red blood cells in thrombosis. Blood 130, 1795\u20131799 (2017).","journal-title":"Blood"},{"key":"1125_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12150","volume":"7","author":"V Bronte","year":"2016","unstructured":"Bronte, V. et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat. Commun. 7, 12150 (2016).","journal-title":"Nat. Commun."},{"key":"1125_CR37","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aay6017","volume":"5","author":"H Alshetaiwi","year":"2020","unstructured":"Alshetaiwi, H. et al. Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics. Sci. Immunol. 5, eaay6017 (2020).","journal-title":"Sci. Immunol."},{"key":"1125_CR38","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1158\/1078-0432.CCR-15-0685","volume":"21","author":"L Mart\u00ednez-Lostao","year":"2015","unstructured":"Mart\u00ednez-Lostao, L., Anel, A. & Pardo, J. How do cytotoxic lymphocytes kill cancer cells? Clin. Cancer Res. 21, 5047\u20135056 (2015).","journal-title":"Clin. Cancer Res."},{"key":"1125_CR39","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/nm.3909","volume":"21","author":"AJ Gentles","year":"2015","unstructured":"Gentles, A. J. et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat. Med. 21, 938\u2013945 (2015).","journal-title":"Nat. Med."},{"key":"1125_CR40","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies, M. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 24, 541\u2013550 (2018).","journal-title":"Nat. Med."},{"key":"1125_CR41","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nm1609","volume":"13","author":"S Nagaraj","year":"2007","unstructured":"Nagaraj, S. et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat. Med. 13, 828\u2013835 (2007).","journal-title":"Nat. Med."},{"key":"1125_CR42","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/nm863","volume":"9","author":"TJ Curiel","year":"2003","unstructured":"Curiel, T. J. et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 9, 562\u2013567 (2003).","journal-title":"Nat. Med."},{"key":"1125_CR43","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1172\/JCI67313","volume":"124","author":"L Deng","year":"2014","unstructured":"Deng, L. et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J. Clin. Invest. 124, 687\u2013695 (2014).","journal-title":"J. Clin. Invest."},{"key":"1125_CR44","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2014.998469","volume":"4","author":"L Levy","year":"2015","unstructured":"Levy, L. et al. Splenectomy inhibits non-small cell lung cancer growth by modulating anti-tumor adaptive and innate immune response. Oncoimmunology 4, e998469 (2015).","journal-title":"Oncoimmunology"},{"key":"1125_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0663-4","volume":"7","author":"MJH van Vugt","year":"2019","unstructured":"van Vugt, M. J. H. et al. Immunogenicity of pembrolizumab in patients with advanced tumors. J. Immunother. Cancer 7, 212 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"1125_CR46","doi-asserted-by":"publisher","first-page":"4286","DOI":"10.1158\/1078-0432.CCR-14-2607","volume":"21","author":"A Patnaik","year":"2015","unstructured":"Patnaik, A. et al. Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin. Cancer Res. 21, 4286\u20134293 (2015).","journal-title":"Clin. Cancer Res."},{"key":"1125_CR47","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1158\/2326-6066.CIR-15-0193","volume":"4","author":"J Weber","year":"2016","unstructured":"Weber, J. et al. Phase I\/II study of metastatic melanoma patients treated with nivolumab who had progressed after ipilimumab. Cancer Immunol. Res. 4, 345\u2013353 (2016).","journal-title":"Cancer Immunol. Res."},{"key":"1125_CR48","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s43018-019-0022-x","volume":"1","author":"S Valpione","year":"2020","unstructured":"Valpione, S. et al. Immune-awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy. Nat Cancer 1, 210\u2013221 (2020).","journal-title":"Nat Cancer"},{"key":"1125_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-021-01146-2","volume":"19","author":"T Cai","year":"2021","unstructured":"Cai, T., Liu, H., Zhang, S., Hu, J. & Zhang, L. Delivery of nanovaccine towards lymphoid organs: recent strategies in enhancing cancer immunotherapy. J. Nanobiotechnology 19, 389 (2021).","journal-title":"J. Nanobiotechnology"},{"key":"1125_CR50","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nrclinonc.2014.111","volume":"11","author":"I Melero","year":"2014","unstructured":"Melero, I. et al. Therapeutic vaccines for cancer: an overview of clinical trials. Nat. Rev. Clin. Oncol. 11, 509\u2013524 (2014).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1125_CR51","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00262-013-1508-5","volume":"63","author":"C Meyer","year":"2014","unstructured":"Meyer, C. et al. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol. Immunother. 63, 247\u2013257 (2014).","journal-title":"Cancer Immunol. Immunother."},{"key":"1125_CR52","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1002\/eji.202048534","volume":"50","author":"J Koh","year":"2020","unstructured":"Koh, J. et al. MDSC subtypes and CD39 expression on CD8+ T cells predict the efficacy of anti-PD-1 immunotherapy in patients with advanced NSCLC. Eur. J. Immunol. 50, 1810\u20131819 (2020).","journal-title":"Eur. J. Immunol."},{"key":"1125_CR53","doi-asserted-by":"publisher","first-page":"5647","DOI":"10.1172\/JCI97570","volume":"128","author":"HM Chen","year":"2018","unstructured":"Chen, H. M. et al. Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity. J. Clin. Invest. 128, 5647\u20135662 (2018).","journal-title":"J. Clin. Invest."},{"key":"1125_CR54","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1038\/s41551-021-00799-6","volume":"5","author":"G Xue","year":"2021","unstructured":"Xue, G. et al. Elimination of acquired resistance to PD-1 blockade via the concurrent depletion of tumour cells and immunosuppressive cells. Nat. Biomed. Eng. 5, 1306\u20131319 (2021).","journal-title":"Nat. Biomed. Eng."},{"key":"1125_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.639722","volume":"12","author":"AM van Cromvoirt","year":"2021","unstructured":"van Cromvoirt, A. M. et al. Donor age and red cell age contribute to the variance in Lorrca indices in healthy donors for next generation ektacytometry: a pilot study. Front. Physiol. 12, 639722 (2021).","journal-title":"Front. Physiol."},{"key":"1125_CR56","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1002\/ajh.25443","volume":"94","author":"MAE Rab","year":"2019","unstructured":"Rab, M. A. E. et al. Rapid and reproducible characterization of sickling during automated deoxygenation in sickle cell disease patients. Am. J. Hematol. 94, 575\u2013584 (2019).","journal-title":"Am. J. Hematol."},{"key":"1125_CR57","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c332","volume":"340","author":"KF Schulz","year":"2010","unstructured":"Schulz, K. F., Altman, D. G. & Moher, D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. Brit. Med. J. 340, c332 (2010).","journal-title":"Brit. Med. J."},{"key":"1125_CR58","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","volume":"28","author":"JR Brahmer","year":"2010","unstructured":"Brahmer, J. R. et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28, 3167\u20133175 (2010).","journal-title":"J. Clin. Oncol."},{"key":"1125_CR59","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.cell.2023.02.021","volume":"186","author":"MK Rahim","year":"2023","unstructured":"Rahim, M. K. et al. Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes. Cell 186, 1127\u20131143 (2023).","journal-title":"Cell"},{"key":"1125_CR60","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/s41591-018-0045-3","volume":"24","author":"X Guo","year":"2018","unstructured":"Guo, X. et al. Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing. Nat. Med. 24, 978\u2013985 (2018).","journal-title":"Nat. Med."},{"key":"1125_CR61","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nbt.4096","volume":"36","author":"A Butler","year":"2018","unstructured":"Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411\u2013420 (2018).","journal-title":"Nat. Biotechnol."},{"key":"1125_CR62","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.cels.2019.03.003","volume":"8","author":"CS McGinnis","year":"2019","unstructured":"McGinnis, C. S., Murrow, L. M. & Gartner, Z. J. DoubletFinder: doublet detection in single-cell RNA sequencing data using artificial nearest neighbors. Cell Syst. 8, 329\u2013337 (2019).","journal-title":"Cell Syst."},{"key":"1125_CR63","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","volume":"175","author":"M Sade-Feldman","year":"2018","unstructured":"Sade-Feldman, M. et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175, 998\u20131013 (2018).","journal-title":"Cell"},{"key":"1125_CR64","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","volume":"21","author":"F Veglia","year":"2021","unstructured":"Veglia, F., Sanseviero, E. & Gabrilovich, D. I. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat. Rev. Immunol. 21, 485\u2013498 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"1125_CR65","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics 16, 284\u2013287 (2012).","journal-title":"Omics"},{"key":"1125_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111384","volume":"40","author":"BP Keenan","year":"2022","unstructured":"Keenan, B. P. et al. Circulating monocytes associated with anti-PD-1 resistance in human biliary cancer induce T cell paralysis. Cell Rep. 40, 111384 (2022).","journal-title":"Cell Rep."},{"key":"1125_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20019-0","volume":"11","author":"Y Zheng","year":"2020","unstructured":"Zheng, Y. et al. Immune suppressive landscape in the human esophageal squamous cell carcinoma microenvironment. Nat. Commun. 11, 6268 (2020).","journal-title":"Nat. Commun."},{"key":"1125_CR68","doi-asserted-by":"publisher","unstructured":"Nie, X. et al. Source data for Extended Data Fig. 2d from \u201cErythrocyte\u2013anti-PD1 conjugates in persons with advanced solid tumors resistant to anti-PD1\/PD-L1: preclinical characterization and results of a phase 1 trial\u201d. figshare https:\/\/doi.org\/10.6084\/m9.figshare.30797153 (2025).","DOI":"10.6084\/m9.figshare.30797153"},{"key":"1125_CR69","doi-asserted-by":"publisher","unstructured":"Yao, X. & Gao, X. GaoXlab\/aPD1_Ery_scripts: v1. Zenodo https:\/\/doi.org\/10.5281\/zenodo.17797265 (2025).","DOI":"10.5281\/zenodo.17797265"}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01125-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01125-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01125-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T14:02:24Z","timestamp":1777471344000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01125-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":69,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["1125"],"URL":"https:\/\/doi.org\/10.1038\/s43018-026-01125-2","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]},"assertion":[{"value":"11 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"X.G. is a founder of Westlake Therapeutics and a member of its scientific advisory board. X.G., X.N. and Y.H. are inventors on a patent application (CN202380026694.3; \u2018An engineered erythrocyte targeting PD1\u2019) submitted by Westlake University and Westlake Therapeutics. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}